Showing 2759 results
-
Press release /Comparison of Jakavi® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1] Additional…
-
Press release /Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018…
-
Press release /Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] Patients had a 65% chance of being…
-
Press release /Study reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to…
-
Press release /Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
-
Ad hoc release /L'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique…
-
Press release /Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
-
Ad hoc release /Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create…
-
Ad hoc release /Die strategische Überprüfung von Alcon ergibt, dass ein 100%iger Spin-off im besten Interesse der Aktionäre ist und im Einklang mit der Strategie von Novartis steht, sich als…
-
Ad hoc release /Erste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei…